Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Programmed axon death, synaptic dysfunction and the ubiquitin proteasome system.

M P Coleman1, R R Ribchester

  • 1The Babraham Institute, Babraham, Cambridge CB2 4AT, UK. michael.coleman@bbsrc.ac.uk

Current Drug Targets. CNS and Neurological Disorders
|June 8, 2004
PubMed
Summary

The neuroprotective gene Wld(S) delays axon degeneration by targeting the ubiquitin proteasome system (UPS). Understanding this regulated cell death pathway is key to developing treatments for neurodegenerative diseases.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Conditional survival of children, adolescents and young adults (0-24 years) diagnosed with leukaemia during 2000-2014 world-wide: (CONCORD-3).

European journal of cancer (Oxford, England : 1990)·2025
Same author

Sex differences in survival from melanoma of the skin: The role of age, anatomic location and stage at diagnosis: A CONCORD-3 study in 59 countries.

European journal of cancer (Oxford, England : 1990)·2025
Same author

Reply to investigating changes over time in socioeconomic gaps in cancer survival: does choice of approach matter?

Annals of oncology : official journal of the European Society for Medical Oncology·2020
Same author

Cancer Survival by Stage at Diagnosis in Kuwait: A Population-Based Study.

Journal of oncology·2019
Same author

Which patients are not included in the English Cancer Waiting Times monitoring dataset, 2009-2013? Implications for use of the data in research.

British journal of cancer·2018
Same author

A review of the peri-operative management of paediatric burns: Identifying adverse events.

South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde·2016

Area of Science:

  • Neuroscience
  • Molecular Biology
  • Genetics

Background:

  • Axon loss is a hallmark of neurodegenerative diseases, impacting both the central and peripheral nervous systems.
  • Wallerian degeneration, a process of axon breakdown after injury, shares mechanisms with neurodegenerative axon death.
  • The neuroprotective gene Wld(S) has shown promise in delaying various forms of axon and synapse loss.

Purpose of the Study:

  • To investigate the role of the ubiquitin proteasome system (UPS) in Wallerian degeneration.
  • To elucidate the specific mechanisms by which Wld(S) confers neuroprotection against axon degeneration.
  • To identify potential therapeutic targets for preventing axon pathology in neurodegenerative disorders.

Main Methods:

  • Utilized the neuroprotective Wld(S) gene as a model system.

Related Experiment Videos

  • Examined the involvement of the ubiquitin proteasome system (UPS) in axon degeneration.
  • Compared the effects of Wld(S) with proteasome inhibitors on neuronal compartments and function.

    • Main Results:

    • Wld(S) delays Wallerian degeneration, axonal dystrophy, and synapse loss.
    • Evidence implicates the UPS in the regulated program of axon death.
    • Wld(S) acts on a specific UPS step, offering a precise and non-toxic approach compared to broad proteasome inhibitors.

    Conclusions:

    • Wallerian degeneration serves as a valuable model for understanding and preventing axon loss in neurodegenerative diseases.
    • Wld(S) represents a promising drug target for neuroprotection by modulating a specific step in the UPS.
    • Further research is needed to define the precise UPS pathway and neuronal compartment targeted by Wld(S) for therapeutic development.